Armata Pharmaceuticals, Inc. (ARMP) has a negative trailing P/E of -2.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -39.70%.
Criteria proven by this page:
Overall SharesGrow Score: 38/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.2 | -0.01 | 0.45 | 16.65 | 1.85% |
| 2017 | -0.5 | 0.01 | 0.83 | 56.10 | - |
| 2018 | -0.3 | 0.00 | 0.46 | 0.00 | - |
| 2019 | -1.3 | 0.02 | 1.74 | 0.00 | - |
| 2020 | -2.2 | 0.05 | 2.60 | 59.53 | - |
| 2021 | -5.7 | 0.20 | 5.20 | 29.52 | - |
| 2022 | -1.2 | -0.09 | 1.18 | 7.72 | - |
| 2023 | -1.7 | -0.02 | -3.65 | 25.81 | - |
| 2024 | -3.5 | 0.05 | -1.39 | 12.93 | - |
| 2025 | -1.3 | 0.00 | -1.04 | 46.41 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-345.80 | $260K | $-18.84M | -7245.4% |
| 2017 | $-27.34 | $115K | $-12.84M | -11163.5% |
| 2018 | $-8.90 | $0.00 | $-12.11M | - |
| 2019 | $-2.43 | $0.00 | $-19.48M | - |
| 2020 | $-1.35 | $823K | $-22.18M | -2695.1% |
| 2021 | $-0.96 | $4.47M | $-23.16M | -517.5% |
| 2022 | $-1.08 | $5.51M | $-36.92M | -670.2% |
| 2023 | $-1.91 | $4.53M | $-69.05M | -1524.5% |
| 2024 | $-0.32 | $5.17M | $-18.92M | -365.6% |
| 2025 | $-4.80 | $4.9M | $-173.8M | -3544% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.09 | $-1.09 – $-1.09 | $5.08M | $5.08M – $5.08M | 1 |
| 2027 | $-1.26 | $-1.26 – $-1.26 | $6.09M | $6.09M – $6.09M | 1 |
| 2028 | $-1.27 | $-1.27 – $-1.27 | $56.29M | $56.29M – $56.29M | 1 |
| 2029 | $-0.75 | $-0.75 – $-0.75 | $27M | $27M – $27M | 1 |
| 2030 | $-0.16 | $-0.16 – $-0.16 | $75.3M | $75.3M – $75.3M | 1 |
